Intraperitoneal ziv-aflibercept effectively manages refractory ascites in colorectal cancer patients

Ascites related to metastatic colorectal cancer (mCRC) reduces patient survival and quality of life, and systemic chemotherapy is largely ineffective for managing ascites. Here, we examined the clinical efficacy of intraperitoneal (IP) ziv-aflibercept for managing refractory ascites in 15 mCRC patie...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Lu, Chieh-Sheng, Lin, Jen-Kou, Chen, Wei-Shone, Lin, Tzu-Chen, Jiang, Jeng-Kai, Yang, Shung-Haur, Wang, Huann-Sheng, Chang, Shih-Ching, Lan, Yuan-Tzu, Lin, Chun-Chi, Lin, Hung-Hsin, Teng, Hao-Wei
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5482690/
https://ncbi.nlm.nih.gov/pubmed/27888621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13543
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares